Gilead Sciences is trading 4.56% up at ARS 71,050 after third-quarter results exceeded analyst expectations and management raised 2026 product-sales guidance. - The October 29 report showed non-GAAP diluted EPS of $2.55; product sales rose 13% year over year to $8.3 billion, or 16% excluding Veklury. - Management set 2026 product-sales guidance at $31.0–$31.3 billion. No reliable trading-volume figure was found for this instrument, so activity level cannot be characterized.